Journal of Clinical Oncology (JCO) Podcast cover art

All Episodes

Journal of Clinical Oncology (JCO) Podcast — 456 episodes

#
Title
1

Adjuvant Durvalumab and the Future of Early-Stage NSCLC

2

JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer

3

Infections in Two Diet Strategies in HSCT and Leukemia Patients

4

JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time?

5

The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC

6

JCO Article Insights: Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC

7

JCO Article Insights: Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026

8

NCI Working Group on Biochemically Recurrent Prostate Cancer

9

Association Between EOL SACT and Healthcare Utilization

10

Milan Consensus Endpoints for Bladder Preservation in MIBC

11

JCO at 2025 ASH: Pirtobrutinib in Untreated CLL

12

JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS

13

JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC

14

Health Outcomes in Older Childhood Cancer Survivors

15

Long-Term Remission After Cilta-cel in Patients With RRMM

16

JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN

17

Income Among Adolescents and Young Adults Surviving Cancer

18

JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs

19

TTFields in Locally Advanced Pancreatic Adenocarcinoma

20

JCO at WCLC: Multinational Pivotal Study of Sunvozertinib in Exon20ins NSCLC

21

Racial and Ethnic Disparities Among Medicare Beneficiaries

22

JCO Article Insights: Lymph Node Dissection for Lung Cancer

23

JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma

24

JCO Article Insights: Pooled Taletrectinib Efficacy and Safety

25

JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

26

JCO at ASCO Annual Meeting: Use of Low-Value Cancer Treatments in Medicare

27

JCO at ASCO Annual Meeting: Avelumab Plus Cetuximab vs. Avelumab in Advanced cSCC

28

JCO at ASCO Annual Meeting: TTFields in Locally Advanced Pancreatic Adenocarcinoma

29

JCO at ASCO Annual Meeting: Lenvatinib Plus Pembrolizumab and Chemotherapy in Gastric Cancer

30

JCO Article Insights: Double Hit Myeloma Correlates With Adverse Patient Outcome

31

Pembrolizumab and Bevacizumab for Melanoma Brain Metastases

32

JCO Article Insights: ESPAC4 Long-Term Follow-Up in Pancreatic Cancer

33

Longitudinal Results from the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment

34

JCO Article Insights: Smoking Assessment

35

Botensilimab Plus Balstilimab in Advanced Sarcomas

36

JCO Article Insights: Long-Term Outcome of Neoadjuvant Chemotherapy for Rectal Cancer

37

High Omega-3, Low Omega-6 Diet with Fish Oil and Prostate Cancer

38

JCO Article Insights: TROPION-Lung01 Dato-DXd in NSCLC

39

Air Pollution and Breast Cancer Incidence

40

JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing

41

Overcoming Barriers to Make Patient-Partnered Research a Reality

42

JCO Article Insights: Nivolumab + Relatlimab v Nivolumab + Ipilimumab in Melanoma

43

Quality of Treatment Selection

44

JCO Article Insights: HLA-Mismatched Unrelated Donor HCT With PTCy

45

Adjuvant Pembrolizumab for High-Risk, dMMR Endometrial Cancer

46

Combining Response and Toxicity Data to Implement Project Optimus

47

CBT-I for Cancer-Related Cognitive Impairment

48

JCO Article Insights: Assisted Reproduction in Breast Cancer Patients

49

Multi-Cancer Early Detection Testing for High-Risk Patients

50

JCO Article Insights: Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade

51

Functional Disability Among US Cancer Survivors

52

CAR T-Cell Therapy for Richter's Transformation

53

EAZ171: Predictors of TIPN in Black Women with Breast Cancer

54

JCO Article Insights: Final Analysis of the Ro-CHOP Trial

55

Methylphenidate for Fatigue in Advanced Cancer

56

Introducing JCO Oncology Advances with Dr. Jonathan Friedberg and Dr. Pamela Kunz

57

JCO Article Insights: Atezolizumab Plus Bevacizumab, Chemotherapy in EGFR, ALK NSCLC

58

Commonly Held Beliefs About Cancer Survivorship

59

JCO Article Insights: Long Term Follow Up of the RESORT (E4402) and LYSA Study

60

Pembrolizumab in Patients With Advanced Cancers With HTMB

61

JCO Article Insights: Axillary Soft Tissue Involvement and Breast Cancer Prognosis

62

Omission of Radiotherapy after Breast-Conserving Surgery

63

Costs of Cancer Prevention in CDH1 Variant Carriers

64

JCO Article Insights: Low and Moderate Grade Adverse Events and the Patient Experience in Clinical Trials

65

Debunking Sex and Disentangling Gender From Oncology

66

Germline EGFR Mutations and Familial Lung Cancer

67

JCO Article Insights: DYPD-Guided Dose Individualization and Survival Outcomes

68

Negative Impact of Prior Authorization on Patients with Cancer

69

Role of Molecular Classification in Predicting Response to Radiation in Early Endometrial Cancer

70

JCO Article Insights: Impact of Physical Activity on Mortality and of BMI on Treatment-Related Adverse Events

71

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

72

JCO Article Insights: Safety and efficacy of a Novel ADC Targeting TROP-2 in Metastatic Non-Small Cell Lung Cancer (NSCLC)

73

Economic Evaluation of a Non-Medical Financial Assistance Program on Missed Treatment Appointments Among Adults With Cancer

74

Disparities in End-of-Life Cancer Care

75

Advance Care Planning in Adolescents and Young Adults with Cancer

76

JCO Article Insights: Improving Lung Cancer Screening Using Blood-Based Biomarkers

77

Impact of Smoking Cessation on Mortality From Kidney Cancer

78

HER3-DXd in EGFR-Mutated NSCLC: HERTHENA-Lung01

79

JCO Article Insights: Introducing The Childhood Cancer Data Initiative

80

Impact of Heatwaves on the Care of Patients With Cancer

81

JCO Article Insights: Immunotherapy in People Living with HIV and Cancer

82

Racial/Ethnic Differences Discovered in Multigene Germline Testing of Early-Onset Colorectal Cancer

83

JCO Article Insights: Two New Prediction Models for Risk of Venous Thromboembolism in Cancer Patients

84

Olanzapine for Chemotherapy-Related Anorexia

85

PROSPECT Trial (Alliance N1048): PROs During and After Treatment for Locally Advanced Rectal Cancer

86

JCO Article Insights: Smoking Cessation for Patients with Cancer

87

JCO Article Insights: Use of Independently-Assessed vs Investigator-Assessed DFS in the APACT Trial

88

Peritumoral Anesthetic Infiltration Impacts Survival in Early Breast Cancer

89

Intensive Caring: Reminding Patients They Matter

90

Barriers to Clinical Trial Participation for Transgender People

91

JCO Article Insights: Trial Update on Development of Children After Maternal Cancer During Pregnancy

92

Cancer Screening During the 2nd Year of the COVID-19 Pandemic

93

Sequencing Matters – Combination Dabrafenib/Trametinib Versus Nivolumab/Ipilimumab for Advanced BRAF-Mutant Melanoma: The DREAMseq Trial

94

JCO Article Insights: Phase III POSEIDON Clinical Trial Results

95

One-Stop-Shop Comprehensive Cancer Screening Center Focused on Asymptomatic Screening

96

Improving Transparency in Phase 1 Clinical Trials

97

JCO Article Insights: Elderly Patients Receiving Chemotherapy for Early-Stage Breast Cancer

98

Ensuring Employment After Cancer Diagnosis

99

Intersectional Maxims for a New Era in Modern Medicine

100

Does Medicare Advantage Lead to a Disadvantage for Patients Who Need Surgery for Cancer?

101

Lack of Gender Equity in Oncology Clinical Trial Advisory Board Membership

102

Universal Germline Genetic Testing in GI Malignancies

103

Light From Darkness - Navigating Postmortem Tissue Donation

104

Physical Activity Improves Survival in Colorectal Cancer

105

Food Insecurity Interventions for Cancer Survivors With Dr. Francesca Gany and Dr. Theresa Hastert

106

How to Confront Climate Change: A Framework for Change in the Operating Room and Hospital as a Whole. A Conversation with Dr. Anaeze Offodile and Dr. Elizabeth Yates

107

JCO After Hours: A Discussion With Veena Shankaran and Scott Ramsey

108

JCO After Hours: A Discussion With Virginia Sun

109

JCO After Hours: A Discussion With Antonio Di Meglio

110

JCO After Hours: A Discussion With Abby Rosenberg and Reshma Jagsi

111

JCO After Hours: A Discussion With Michael Gnant and Kathy Miller

112

JCO After Hours: A Discussion With Kirsten Beyer and Jennifer Griggs

113

Is Dose-Adjusted EPOCH-R the Optimal Treatment for Children with Primary Mediastinal B-Cell Lymphoma?

114

Steroid Dose and Taxanes

115

Commentary on GROINSS VII

116

Harnessing the Power of Registries to Understand the Impact of Treatment for Hodgkin Lymphoma on Fertility

117

Subspecialty Palliative Care Involvement May Lessen the Need for High-Intensity End-of-Life Care for Adolescents and Young Adults With Cancer

118

Can the Incorporation of Minimal Residual Disease Detection Enhance Post-CAR T Outcomes in Patients With Large B-Cell Lymphoma?

119

Moving Forward With Venetoclax-Based Combinations in Younger Adults With Acute Myeloid Leukemia

120

A Deep Dive Into HLA Typing For Unrelated Donor Hematopoietic Cell Transplantation

121

PENELOPE-B: Exploration of CDK4/6 Inhibition in the Adjuvant Setting

122

ctDNA in DLBCL: A Blueprint for Better Clinical Trials?

123

How Can We Expand Eligibility Criteria for Diffuse Large B-Cell Lymphoma Clinical Trials to Serve More Patients?

124

The Pathologist, the Surgeon, and the Rare Phyllodes Tumor

125

Cancer Surgery in COVID-19-Free Facilities

126

Finding a Needle in a Haystack of Mutations: Using Whole Genome Sequencing to Identify Patients with Low-Risk Myeloma

127

Advancing Knowledge on the Use of Dexrazoxane in Children With Acute Myeloid Leukemia and Other Childhood Cancers

128

Better Diet – Fewer Side Effects?

129

Genetic Testing in Breast Cancer Patients: Striking the Balance Between Over Versus Undertesting

130

High Reward, High Toxicity: Combination Pembrolizumab and Lenvatinib in Advanced Endometrial Cancer

131

Optimizing Treatment Strategies for Germline BRCA/PALB2 Mutant Pancreatic Adenocarcinoma

132

Immune Checkpoint Inhibitor Use in Patients With Inflammatory Bowel Disease: A Closer Look

133

The High Prevalence of Exercise Intolerance in Adult Survivors of Childhood Cancer Is Predictive of All-Cause Mortality

134

Leptomeningeal Disease in EGFR-Mutated Lung Cancer: Can We Finally Define a Standard Treatment?

135

Advancing Treatment Options for Mismatch Repair-Deficient Metastatic Colorectal Cancers

136

Keeping Mycosis Fungoides in Check: A Study of Pembrolizumab for Relapsed/Refractory MF and Sezary Syndrome

137

What's in a Name? An Introductory Guide

138

Resuming Life After Cancer Therapy: Treatment-Free Survival

139

Intratumoral Immune Infiltration in Follicular Lymphoma: Novel Insights into Early Relapse and Survival

140

MYC Rearrangements in Diffuse Large B-Cell Lymphoma: Impact and Implications for Diagnostic Testing

141

Centralization of High-Risk Surgery: Real Benefits for Patients From Health Systems

142

Microsatellite Instability as a Prognostic Marker for Resectable Gastric Cancer and a Potential Biomarker for Perioperative Chemotherapy Benefit

143

Radiotherapy Dose Reduction Is Possible With Induction Chemotherapy for Pediatric Nasopharynx Cancer

144

Fine Tuning Therapy for Intermediate-Risk Neuroblastoma Using Clinical Response and Tumor Biology

145

Déjà Vu or Predicted: The Failure of Dose Adjusted EPOCH-R to Improve Outcomes in Diffuse Aggressive Lymphomas

146

Tackling Stage III EGFR Mutation-Positive Lung Cancer: Do We Really Know How?

147

The Need for Continued Vigilance in Patients with Diffuse Large B-Cell Lymphoma

148

A Second Chance at Checkpoint Inhibition After Initial Immune-Mediated Diarrhea and Colitis

149

Anticipating the Future of Hodgkin Lymphoma

150

An Advance for the Treatment of Osteosarcoma

151

The Heartbreak of Cancer Treatment: The Latest in Late Cardiac Toxicity

152

Programmed Cell Death-1 Pathway Inhibitors Enter Center Stage as First-Line Treatment of Advanced Merkel Cell Carcinoma

153

Potential for Parenthood After Childhood Cancer: Perceptions and Reality

154

How Should We Interpret Indeterminate Pulmonary Nodules at Diagnosis in Children With Rhabdomyosarcoma?

155

The End of ENDoxifen Metabolite and CYP2D6 Testing in Tamoxifen-Treated Women?

156

Less is More: Precision Surveillance Imaging for Wilms Tumor

157

How Low Can You Go? Impact of Baseline Corticosteroid Use on Immunotherapy Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer

158

Expanding Treatment Options for Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

159

The Addition of Another Camptothecin Fails to Improve Outcomes in Patients With Intermediate-Risk Rhabdomyosarcoma

160

The Addition of IKZF1 Deletion in Risk Stratification for Children with Newly Diagnosed B-Acute Lymphoblastic Leukemia Leads to Improved Survival: Results of the Malaysia-Singapore ALL 2010 Study

161

Psychosocial Outcomes Following Contralateral Prophylactic Mastectomy: Insights and Opportunities

162

Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms

163

Don't Treat Me Like a Child: The Intensification of Conventional Chemotherapy in Adults With Acute Lymphoblastic Leukemia

164

Multiple Myeloma Joins the Car T Race

165

Cardiotoxicity After Breast Cancer Radiotherapy: Which Part of the Heart Matters Most?

166

Should Prophylactic Cranial Irradiation Be Used in Patients with Stage III Non-Small Cell Lung Cancer?

167

The Medical Marijuana Conundrum: When Public Interest Outpaces Medical Knowledge

168

Racial Disparities in Medical Financial Hardship Among Cancer Survivors

169

Late Infectious Death: Asplenic Adult Survivors of Child Cancer

170

Extending the Reach of Targeted Therapy for Hormone Receptor-Positive Advanced Breast Cancer

171

An International Phase II Trial of Single-Agent Nivolumab for Hodgkin Lymphoma Relapsed or Refractory After Autologous Stem Cell Transplant

172

Exploring a New Delivery Model for Germline Genetic Testing for Patients With Ovarian Cancer

173

Is Earlier Treatment Better For Patients? The Case of Docetaxel in Metastatic Castration-Sensitive Prostate Cancer

174

The Decision to Image Breast Cancer Patients with Local-Regional Recurrence

175

The Importance of Reading Clinical Trial Protocols Simultaneously With Published Studies

176

Understanding the 'Value-Added' by Specialized Pediatric Palliative Care Teams in the Care of Children With Cancer at the End of Life

177

Survival Following Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Early-Stage Hepatocellular Carcinoma

178

The True Costs of the 21-Gene Assay in a Cohort of 1,000 Patients

179

Persistent Use of Opioids After Cancer Surgery

180

Discussion on the Cost–Effectiveness Analysis of the CALGB/Alliance Trial and the Use of Zoledronic Acid Generic in Women With Metastatic Breast Cancer

181

Can We Simplify the Treatment of Myelofibrosis?

182

Lessons to be Learned about the Significance of Educational Level in Adults with Acute Myeloid Leukemia

183

More Often but Not Early: Hospice Use Among Older Adults With AML

184

T-cell Therapy for Viral Infections after Stem Cell Transplant

185

Shared Risk Factors in Cancer and Cardiovascular Disease: Can We Make a Difference?

186

Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?

187

Considerations in Predicting Neuropsychological Outcomes in Children Treated for ALL

188

Low-Income Subsidy and Financial Barrier to Access Costly Oral Chemotherapy Drugs for Myeloma Patients Enrolled in Medicare Part D

189

Beyond the Beam: Thinking about Subsequent Malignancy Risk Outside of the Radiation Paradigm,"

190

Discussion of the SWORD-Study and Fear of Cancer Recurrence Intervention Research Randomized Controlled Trial

191

Optimizing Up-Front Therapy for Double-Hit Lymphoma

192

Chronic Conditions in Cancer Survivors

193

Do Treatment Summary Survivorship Plans Make Any Difference?

194

The Impact of Cigarette Smoking on Survival in Patients with Pancreatic Cancer

195

Better Patient-Reported Outcomes After Autologous Breast Reconstruction Compared to Implant-Based Reconstruction Study

196

Drugs Don't Work in Patients Who Don't Take Them

197

Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma

198

Long-Term Follow-up of AF-001JP: A Phase I/II Study of Alectinib in ALK-Positive NSCLC

199

Late Relapse in Hodgkin Lymphoma Persisting Even at 20 Years: Implications for Therapeutic Intensity and Disease Biology

200

Intensification of Consolidation Therapy for Acute Myeloid Leukemia by the Addition of Clofarabine to Cytarabine Improves Relapse-Free Survival

201

Characterizing the Patterns of Clonal Evolution in Ibrutinib-Treated CLL: A Roadmap for Continued Progress

202

Prevalence of Germline Mutations in Individuals With Colorectal Cancer as Determined Using a Multi-Gene Panel Test

203

Financial Barriers to Cancer Care for Patients Obtaining Insurance on the Federal Exchange

204

Mindfulness-Based Interventions in Oncology: Not for Everyone?

205

The Impact of Oral Targeted Therapies on the Cost of Care for Patients With Chronic Lymphocytic Leukemia

206

Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

207

Getting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac Dysfunction

208

Listen to Your Patients

209

Impact of Organizational Characteristics and Process of Care on Hospital Mortality and Resource Use in Cancer Patients Admitted to Intensive Care Units

210

Health-Related Quality of Life: Increasingly Important in the Era of Effective, Modern Myeloma Therapy

211

Chemotherapy Induced Peripheral Neuropathy: A Novel Method of Exploration

212

Changes in the Epidemiology of AIDS-Related Kaposi's Sarcoma and Lymphomas: How This Informs the Clinician

213

Implicit Racial Bias Affects Key Aspects of Physician Communication

214

Nivolumab Monotherapy is Safe and Active in Hematologic Malignancies

215

Minimizing Frailty in Cancer Survivors: A Meaningful Goal for All Ages

216

1q Gain, a Prognostic Biomarker in Nephroblastoma, and What's Next?

217

Therapy Impacts Long-Term Survival for Patients in Germany With Heritable Retinoblastoma

218

Dexamethasone and High-Dose Methotrexate in High-Risk B Cell Acute Lymphoblastic Leukemia—Where Should We Go From Here?

219

Unraveling the Significance of Mismatch Repair Deficiency in Women With Endometrioid-type Endometrial Adenocarcinoma

220

Nodal Status After Neoadjuvant Chemotherapy Determines Prognosis in Localized Gastric Cancer

221

Restrictions on Nutrition, Social Contacts, and Pets Are Not Effective Anti-Infective Measures in Children With Acute Myeloid Leukemia

222

Current Status of Supplemental Screening in Dense Breasts

223

Selective Internal Radiation Therapy for Liver-Dominant Metastatic Colorectal Cancer: Time to Put the Brakes On?

224

Prognostication Based on Site of Metastatic Disease in Castration Refractory Prostate Cancer: Implications for Patient Care and Clinical Trial Design

225

IgM-Related AL Amyloidosis: A Rare Form of a Rare Disease

226

Quality of Life: A Critical Consideration in Women Diagnosed with Ductal Carcinoma in Situ

227

Very Late Outcomes of Wilms Tumor Survivors: British Childhood Cancer Study

228

Web-Based Technology Can Improve Patient Understanding and Preparedness to Discuss Cancer Clinical Trials: One Step Towards a Goal of Increased Enrollment

229

How Should We Manage the Financial Toxicity of Cancer Treatment?

230

Prognostication in Mantle Cell Lymphoma

231

Sunbelt Melanoma Trial: A Seminal Adjuvant Interferon Trial with Long Term Results

232

Hepatocellular Carcinoma in Children and Adolescents: Time for a Strategy and a Trial

233

Clinical Drug Development for Non-Muscle-Invasive Bladder Cancer…Definitions Matter

234

Race for the Cure: How differences in Race and Ethnicity Impact the Diagnosis and Survival of T-Cell Lymphoma

235

Epidural Spinal Cord Compression: The Importance of Multi-disciplinary Treatment Planning

236

Hard to RECIST: Updating and Simplifying Primary Tumor Response Guidelines for the Revised International Neuroblastoma Response Criteria (INRC)

237

Expanding Immunotheapy Benefit in Metastatic RCC

238

A New Oncogene Target in Lung Cancer: Exon 14 Alterations in the MET Gene

239

The Evolution of the Polycythemia Vera Symptom Burden: Implications for a Changing Treatment Paradigm

240

The Emerging Role of Gallium-68 Somatostatin-Receptor PET Imaging in Neuroendocrine Tumors

241

Dexrazoxane for childhood cancer patients – ready for prime time?

242

Uterine lavage: a new approach to gynecologic cancer detection?

243

Hormonal Therapy is Out for Meningiomas: Time to Change Tactics?

244

Defining the Optimal Interval for Colonoscopic Screening in Individuals with a Family History of Colorectal Cancer

245

Using the CLIC Study of Outcome in Advanced Stages of Mycosis Fungoides and Sezary Syndrome to Guide Treatment And Clinical Research

246

Geographic Access as a Barrier to Adjuvant Chemotherapy for Patients with Stage III Colon Cancer

247

Host Factors and Lynch Syndrome Patients: Weighing Role of Obesity and Aspirin and Risk of Colorectal Cancer

248

To Stop or Not to Stop: That is the Question

249

Breast Cancer and Weight Loss: Where Do We Go from Here?

250

The Promise and the Pitfalls of Population-Wide Screening of BRCA1 and BRCA2

251

Intraperitoneal Therapy for Ovarian Cancer: No More Excuses

252

Balancing Safety and Efficacy in the Treatment Hodgkin Lymphoma: Early Discontinuation of Certain Drugs Can and Should Be Done

253

When Toxicity and Efficacy Collide

254

First Results of Euramos I and Logistics of International Collaboration for Clinical Trials of Rare Diseases

255

Treatment Advances in Local-Regionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree that More Isn't Always Better?

256

Androgen Deprivation Therapy for Prostate Cancer - Friend or Foe to the Psyche?

257

Building Blocks in the Case for Adjuvant Therapy in Biliary Tract Cancers

258

Aromatase Inhibitor Arthralgias: Identification, Treatment Options and Research Perspectives

259

Deciphering the Heterogeneity Within EGFR-mutant Lung Cancer

260

Precision Immunology: The Promise of Tumor Immunotherapy for the Treatment of Cancer

261

The Importance of Discussing Genetics with Every Breast Cancer Patient

262

Hematopoietic Stem Cell Transplant for Children With Acute Lymphoblastic Leukemia at BFM Centers: Comparable Results With Matched Sibling Donors and Matched Unrelated Donors

263

Is It Biology or Brawn in Ovarian Cancer Surgery?

264

Mirror Views: Reflections of Complementary Perspectives in Patient and Clinician Toxicity Reporting

265

Dynamic Evolution of ALK Positive Non-Small Cell Lung Cancers and Management of Associated Brain Metastases

266

Prediction of Breast Cancer Risk After a Benign Breast Biopsy: A Practical Model?

267

Prophylactic Anticoagulation in High-Risk Metastatic Germ Cell Tumor Patients: Who Should We Treat?

268

The Risk of Second Cancers for Patients with Endometrial and Rectal Cancer Receiving Radiation Therapy

269

Better Outcome of Chemo-Irradiation of Head and Neck Cancer in High-Patient-Volume Institutions

270

Is There a Future for Cyclooxygenase-2 Inhibition in Non-Small Cell Lung Cancer?

271

The Treatment of Insomnia in Cancer Patients

272

The Biopsy Study: How the Use of Multiple Colposcopic-Directed Biopsies Improves Detection of Cervical Precancers

273

Intensified Frontline Chemoimmunotherapy with R-ACVBP May Improve Outcomes for Younger Patients with Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

274

A Positive Study of DTC-Guided Secondary Adjuvant Treatment in Early Breast Cancer: Ready for Prime Time?

275

A Second Course of Radiation Therapy for Painful Osseous Metastases Improves Patient Function and Quality of Life

276

Adjuvant Trastuzumab Passes the Test of Time

277

Prognostic Value of BRAF V600 E Mutation in Papillary Thyroid Cancer

278

Biochemotherapy: As Time Goes By?

279

The First Prospective Trial of Proton Therapy for Children With Rhabdomyosarcoma: What We Learn From Preliminary Results

280

Intermediate Risk Pediatric Hodgkin Lymphoma: Early Response-Adapted Treatment Is Key

281

Keeping Older Cancer Patients out of the Hospital: A Community Affair

282

Optimal Duration of MRD Monitoring During Therapy for Childhood ALL

283

Hepatitis B Reactivation in Patients Receiving Rituximab Can Be Detected Early and Managed with Antivirals

284

CT or No CT: An Important Question in Diffuse Large B-Cell Lymphoma

285

Glembatumumab Vedotin (CDX-011, CR011-vcMMAE): On The Brink Of Targeted Therapy For Triple-Negative Breast Cancer?

286

Post-Transplant Cyclophosphamide for GVHD Prophylaxis: Back to the Future

287

The Price Of A Drug is Not the Whole Cost

288

Cabozantinib in Advanced Prostate Cancer: Is the Therapeutic Window Too Narrow?

289

Fracture Risk after Cystectomy: Don't Ignore It

290

Is Hematopoietic Stem Cell Transplantation of Value in Treating Systemic Mastocytosis?

291

Significant Dose Effect of Radiotherapy to the Pancreas and Risk of Diabetes Mellitus in Long-Term Hodgkin Lymphoma Survivors

292

The End of Rituximab Maintenance for Low Tumor Burden Follicular Lymphoma

293

Use of Mutational Analysis to Help Decide Whether Patients with Myelodsysplastic Syndromes Should Receive Allogeneic Hematopoietic Cell Transplant

294

Why are Fellows' Burnout Rates as High as Those of Practicing Oncologists?

295

Surprisingly Good Results in BCR-ABL1-like Pediatric Acute Lymphoblastic Leukemia: What Do They Mean?

296

Should Corticosteroids Be Used for the Treatment of Pain, Fatigue and Loss of Appetite in Cancer Patients Receiving Opioids?

297

Breast Reconstructions: Inequities in Access Affecting Choice and Quality

298

Recurrent/Metastatic Human Papillomavirus-Associated Oropharynx Cancer: What Happens When This Good Prognostic Cancer Misbehaves?

299

Long Term Cardiac Safety Data from the HERA Adjuvant Trastuzumab Trial

300

Breast Needle Core Biopsy: The Impact Surgeons and Geography Have on Utilization and the Impact on Patient Care

301

Identifying High-Risk Myeloma

302

Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab

303

Breast Cancer Chemotherapy Effects on Brain Activation During Multitasking and Relation to Cognitive Complaints

304

Delayed Diagnostic Lumbar Puncture to Optimize Central-Nervous-System-Directed Therapy in Childhood Acute Lymphoblastic Leukemia

305

Capecitabine Versus Continuous Infusion 5-FU for Rectal Cancer Neoadjuvant Chemoradiation: Equivalent Effectiveness Raises Real-World Questions About Efficacy, Adherence and Economic Implications

306

Evolving Treatment Paradigms for Primary Mediastinal Diffuse Large B-Cell Lymphoma

307

Response Assessment in Hodgkin Lymphoma: Size Matters!

308

Second Tumors in PTEN Mutation-Positive Patients: Are They Recurrences or New Primaries?

309

Are Partners of Patients HPV-Positive Oropharyngeal Cancer at Increased Risk of Infection and Cancer?

310

Planning to Survive: The Role of Physicians

311

Minimal Residual Disease (MRD) Study to Optimize Definition and Therapy of High-Risk Acute Lymphoblastic Leukemia

312

Risk-Reducing Oophorectomy in Women with BRCA1 and BRCA2 Mutations: An Opportunity to Personalize Recommendations for Cancer Prevention

313

Anti-EGFR Monoclonal Antibodies in the First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The PEAK Experience

314

Accuracy of BRCAPRO in Women with Ovarian Cancer

315

Serious Bevacizumab-Associated Gastrointestinal Toxicity

316

The Efficacy of Bevacizumab Combined with Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer Patients and Its Effects On Patient-Reported Outcomes

317

Nivolumab: Promising Survival Signal Coupled with Limited Toxicity Raises Expectations

318

Decision Shared or Otherwise-: The Ongoing Evolution of Local Therapy for Breast Cancer

319

Is Early Initiation of Adjuvant Chemotherapy for Breast Cancer Better?

320

Single Agent Rituximab Active in Nodular Lymphocyte Predominant Hodgkin Lymphoma

321

Adjuvant Treatment for Gastric Cancer: The Story Continues to Evolve

322

Benefits of Modified Craniospinal Radiation Therapy for Children Treated for Medulloblastoma: Preserving Long-Term Neurocognitive Function

323

Breast MRI As It Is, In Contrast To How We Wish It To Be

324

New Adoptive T Cell Therapy Has EBV-Positive Lymphomas on the Run

325

Adjuvant High-Dose Interferon: New Evidence Regarding Treatment Duration and Survival Impact in Melanoma

326

Some like It Even Hotter: Escalating Radioimmunotherapy in Follicular Lymphoma?

327

Increasing Cytarabine Dose in AML Induction Improves Outcomes in Younger Patients

328

The Value of Preoperative MRI in Predicting Outcome in Patients with Rectal Cancer

329

Refining Stringency of Response in Myeloma

330

When Hodgkin Lymphoma Relapses in The Older Patients

331

How Do We Decide Who Should Be Offered a Sentinel Node Biopsy When Their Melanoma Is Less than 1mm in Thickness?

332

FISH for Smoldering Multiple Myeloma

333

External Beam Accelerated Partial Breast Irradiation: Exploring the Limits of Tolerability

334

Minimal Residual Disease (MRD) in Acute Myeloid Leukemia- Are we Ready for Individualized Risk Assessment Based on MRD?

335

Functional Imaging as a Biomarker for Survival in Locoregionally Advanced Non-Small Cell Lung Cancer Patients

336

EORTC 18961 GMK Vaccine Adjuvant Trial: Unfulfilled Promise for Another Vaccine Trial

337

Lenalidomide Monotherapy for Relapsed Mantle Cell Lymphoma

338

Flying Solo: Chemotherapy Without Radiation for Primary Central Nervous System Lymphoma

339

Second Hematopoietic Transplants for Relapsed AML

340

In End-Of-Life Decision-Making, Does DNR Measure Up?

341

A Clear Answer to the Wrong Question

342

Bisphosphonate-Related Osteonecrosis of Jaw (BOJN) in the Adjuvant Breast Cancer Setting: Risks and Perspective

343

Should Myeloma Residual Disease Become a Standard Assay for Large Cooperative Groups and Myeloma Referral Centers?

344

The Prognosis of Breast Cancer Diagnosed During Pregnancy

345

The SUCCEED Trial: Maintenance Ridaforolimus for Metastatic Soft- Tissue Sarcomas

346

Who Needs What Therapy? The Elusive Search for Predictive Markers

347

Micro RNAs and Other Molecular Markers in AML Therapeutics

348

Neuroanatomic and Neuropsychological Outcomes in Adults after Treatment for Childhood Acute Lymphoblastic Leukemia

349

HERA Indicates that Adjuvant Trastuzumab Confers Equal Benefit for HER2-Positive Invasive Ductal and Invasive Lobular Breast Cancers

350

New Evidence of the Clinical Significance of Cigarette Smoking by Colon Cancer Patients

351

Radiotherapy for Pediatric Hodgkin Lymphoma: Are We Ready To Say Goodbye?

352

Minimal-Intensity Conditioning: A Decade Later

353

Evolution of Concurrent Chemoradiation Treatment Approaches in Head and Neck Cancer

354

Off-Label Cancer Therapy Use: How Much is Too Much?

355

Caring For Patients With Transformed Follicular Lymphoma

356

Outpatient Therapy for Fever and Neutropenia is Safe But Implementation is the Key

357

Outcomes in Cancer Survivors Who Develop Second Malignant Neoplasms

358

Molecular Profiling of Gastric Cancer: Toward Personalized Cancer Medicine

359

Reflections on "Cancer Survivorship": Evolution, Utility, and Acceptability

360

Estimating the Risk for Contralateral Breast Cancer as a Guide for Surgical Treatment

361

Revisiting Combination TACE-RFA Treatment for HCC

362

Novel Insights From a Phase II MEK Inhibitor Trial in BRAF Mutant Melanoma

363

Successful Non-Intensive Bridging of MDS Patients Towards Allografting

364

Using a Video Decision Support Tool for CPR Decision-Making

365

Radioimmunotherapy for the Initial Treatment of Follicular Lymphoma

366

Management of Metastases to the Brain: A Therapeutic Conundrum

367

Understanding the Role of MET Kinase in Cancer Therapy

368

AIDS Related Lymphomas - More Options and More Questions

369

Long Term Follow-up of NSABP B-31: How Well Can We Predict Cardiac Toxicity with Trastuzumab?

370

More Adjuvant Chemotherapy is Not Always Better

371

Hodgkin Lymphoma: Protecting the Victims of Our Success

372

Beyond the Plasma Cell: Proteasome Inhibition in Acute Myelogenous Leukemia

373

Breast Brachytherapy in the United States: Increasing Use Despite Increased Complication Rates

374

Referral Practices to Palliative Care Among Canadian Oncologists

375

Clinical Utility of Screening Tests in Asymptomatic Long-Term Childhood Cancer Survivors

376

Is Lymphatic Mapping Ready for Clinical Use in the Treatment of Squamous Vulvar Cancer?

377

Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation: Final Analysis of the CORAL Trial

378

Informed Consent for Pediatric Phase I Cancer Trials: An End-of-Life Decision

379

Outcome in Systemic Anaplastic Large Cell Lymphoma: Beyond ALK

380

Should Gemtuzumab Ozogamicin Be Re-added to the Therapeutic Armamentarium for Acute Myeloid Leukemia?

381

Immunohistochemical Double Hit Score in Diffuse Large B-Cell Lymphoma: The Potential to Screen All Tumors for High-Risk Biology

382

In a Sea of Data the Water is Still Murky: Meta-Analysis of Cognition in Breast Cancer

383

KRAS G13D Mutations in Metastatic Colorectal Cancer: Are They Different From Codon 12?

384

Taxane Induced Peripheral Neuropathy: A Continued Challenge but Not a Biomarker of Treatment Efficacy

385

Is This Nomogram Ready To Roll?

386

Adjuvant Chemotherapy in Older Patients with Stage III Colon Cancer

387

The Combination of Bortezomib, Thalidomide, and Dexamethasone in Relapsed Multiple Myeloma

388

Personalized Therapy for Breast Cancer: Is It Really Happening?

389

Routine Second Pathology Review for Node-Negative Breast Cancer: What is Learned and What is the Effect on Patient Care?

390

Pre-Operative Metformin in Early-Stage Breast Cancer

391

Fulvestrant and Anastrozole in Combination: FACT or Fiction?

392

A New Day Dawning for Hodgkin Lymphoma?

393

The German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow Up of 11 Years: Implications of Long Term Follow Up

394

Carboplatin-Gemcitabine-Bevacizumab: Expanding Treatment Options for Recurrent Platinum Sensitive Epithelial Ovarian Cancer

395

The Use of Adjuvant Therapy in Elderly Patients with Resected Non-Small Cell Lung Cancer (NSCLC)

396

Management and Prevention of Pain Related to Treatment or Disease

397

1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting

398

Management of Low Stage Ovarian Clear Cell Carcinoma

399

Surviving Childhood Cancer: Defining Risk of Poor Cardiac Outcomes in Early and Middle Adulthood

400

No Advantage to Combining Cetuximab with 5FU, Leucovorin, and Oxaliplatin in Metastatic Colorectal Cancer

401

Sorting Through Early Melanomas to Identify Those at Higher Risk for Metastases

402

Sedation for the Management of Refractory Suffering

403

The Role of the Estrogen Receptor (ER) in Selecting Women, Diagnosed with DCIS for Adjuvant Therapy with Tamoxifen

404

How Cooperative Group Trials Impact Breast Cancer Care in United States

405

What's Different Between One Colorectal Cancer and Another? It's All in the Genes

406

Molecular Tumor Analyses Followed by First Line Oral Tyrosine Kinase Inhibitors in Lung Adenocarcinomas with Driver Abnormalities

407

Placing the P Value into Perspective: Does Paclitaxel Add Value to Gemcitabine and Cisplatin in Advanced Urothelial Cancers?

408

Early Stage Hodgkin Lymphoma -- How Much is Enough?

409

The Rich Get Richer: Another Efficacious Option for Refractory Hairy Cell Leukemia

410

Rethinking Our Use of CSFs in the Adjuvant Treatment of Women Who Have Estrogen Receptor Positive Cancers

411

Recurrence and Survival Results of the GOG Lap2 Trial Confirm Safety of the Laparoscopic Approach to Surgical Staging and Treatment for Uterine Cancer

412

"Anything You Can't Do, I Can't Do Either": Transplantation for High Risk AML

413

Safety and Efficacy of Sequential Adjuvant AI Therapy in ER Positive Breast Cancer

414

The Role of Ovarian Suppression for Fertility Preservation in Women Receiving Adjuvant Breast Cancer Chemotherapy

415

Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib

416

The Importance of Tumor Biopsies for Analysis of Mechanisms of Response and Resistance in Prostate Cancer

417

Targeting the Angiopoietin-Tie2 Axis: A Promising Alternative Antiangiogenic Strategy for Epithelial Ovarian Cancer

418

Interim PET Scans in Diffuse Large B-Cell Lymphoma - More Than Another Biomarker?

419

To Biopsy or Not to Biopsy? That is the Question

420

Disparities in Systemic Therapy for Breast Cancer

421

Adjusting for Treatment Cross-Over to Enable Analysis of Longer Term Outcomes in the MA.17 Trial

422

Obesity and Colorectal Cancer: What's the Big Deal?

423

Combinations or Single Agents, Crossover or No Crossover: Considering Chemotherapy Strategies in the Multi-Chaptered Story of Metastatic Breast Cancer

424

Medical Oncologist Attitudes and Practice in Cancer Pain Management: A National Survey

425

Is a "Wait and See" Nonoperative Approach Justified after Chemoradiation for Rectal Cancer

426

Predictive Testing for BRCA1/2 Mutations: The Value of the "True"Negative

427

Trastuzumab in the Adjuvant Setting - Sequential versus Concurrent: Will We Ever Know the Full Answer?

428

Solving the Mystery of Recurrence in "Surgical Cures" for Early Non-Small Cell Lung Cancer

429

Comorbidity Data in Cooperative Trials: Feasible and Non Ignorable

430

Gender Equity and HPV-Associated Cancers in the United States

431

Biomarker Selection for Maintenance Therapy in Advanced NSCLC

432

Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia

433

R-CHOP Chemotherapy as Upfront Treatment for Advanced Stage Follicular Non-Hodgkin Lymphoma

434

Venlafaxine and Clonidine for Treatment of Hot Flashes in Women with Breast Cancer

435

Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Non-Carriers: A Single Institution Experience

436

Individualizing the Risk of Cardiovascular Mortality Following Androgen Deprivation Therapy for Prostate Cancer

437

High Risk Stage II Colon Cancer: What is the Role of Adjuvant Chemotherapy?

438

Is Genotype Guided Tamoxifen Dosing Ready for Prime Time?

439

Menopausal Hormone Therapy, Mammographic Density and Breast Cancer

440

The Growing Value of Risk Calculators for Men Considering Prostate Cancer Screening

441

Interpretation of the Biomarker Analysis and Final Overall Survival Results from IPASS

442

Curing Leukemia with a Single Drug

443

Vaccination with an Autologous Idiotype Based Vaccine Following a Chemotherapy Induced Remission Holds Promise in the Treatment of Patients with Follicular Lymphoma

444

Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer

445

MEK Inhibitors

446

Angiogenic Therapy in Breast Cancer: Axitinib with Chemotherapy Joins the Crowd

447

Advanced Radiation Therapy Technology Improves Survival in Lung Cancer

448

The Dark Side of del(5q) MDS

449

Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer: Is it Ready for Prime Time?

450

Are Lung Cancers with BRAF Mutations Another Molecularly Defined Subgroup of Patients?

451

Targeting the VEGF Receptor in Colon Cancer: Lessons Learned from Negative Trials

452

The Performance of Breast MRI Screening Among Women with BRCA1/2 Mutations

453

Circulating Tumor Cells in Resectable Colorectal Cancer

454

Results From a Phase I Trial of TG101348, a Selective JAK2 Inhibitor with Significant Activity in Symptomatic Myelofibrosis Patients

455

RIBBON-1 Revisited

456

Noninferiority of Denosumab As Compared With Zolendronic Acid With Respect to the Ability to Delay Skeletal Events in Patients With Solid Tumors and Multiple Myeloma